●被担保人诺迪康医药为本公司控股子公司；本次担保不存在关联担保。 ●本次担保是否有反担保：被担保控股子公司以其相应资产向本公司提供反担保。 证券代码：600211 证券简称：西藏药业 公告编号：2023-044 西藏诺迪康药业股份有限公司 关于公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●本次担保金额及已实际为其提供的担保余额：本次我公司为控股子公司西藏诺迪康 医药有限公司（以下简称"诺迪康医药"）提供担保金额为人民币 20,000 万元。本次担保 前，公司对诺迪康医药提供的担保余额为 34,500 万元。截至本公告日，公司已实际为诺迪 康医药提供的担保余额为人民币 54,500 万元。 ●对外担保逾期的累计数量：无。 一、担保情况概述 （一）担保基本情况 根据公司生产经营及业务发展的需要，近日公司为下属控股子公司诺迪康医药向银行 申请的 1 笔综合授信业务提供连带责任保证，我公司与中国民生银行股份有限公司拉萨分 行（以下简称"拉萨民生"）签订《保证合同》，为诺迪康医药与拉萨民生的授 ...

西藏诺迪康药业股份有限公司 证券简称：西藏药业 证券代码：600211 编号：2023-042 关于 2023 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于 2023 年 9 月 14 日（星期四）下午 15:00-16:00 在上海证券交易所上证路演 中心（网址：http://roadshow.sseinfo.com/），以网络文字互动方式召开了公司 2023 年半 年度业绩说明会，现将召开情况公告如下： 一、业绩说明会召开情况 本公司于 2023 年 9 月 5 日在《中国证券报》《上海证券报》《证券时报》及上海证券交易 所网站（www.sse.com.cn）披露了《关于召开 2023 年半年度业绩说明会的公告》。2023 年 9 月 14 日下午 15:00—16:00，公司董事长陈达彬先生、总经理郭远东先生、副总经理兼董秘 刘岚女士、财务总监陈俊先生、独立董事满加云先生出席了本次业绩说明会，并与投资者进 行互动交流和沟通，就投资者关注的问题进行了回复。 二、投资者提出的问题 ...

四川良禾律师事务所 关于西藏诺迪康药业股份有限公司 2023 年第一次临时股东大会的法律意见书 致: 西藏诺迪康药业股份有限公司 四川良禾律师事务所(以下简称"本所")接受西藏诺迪康药业 股份有限公司（以下简称"公司"）的委托,指派陈曾珍、安东律师 出席公司 2023 年第一次临时股东大会,并依据《中华人民共和国公 司法》（以下简称"《公司法》"）、《上市公司股东大会规则》（以 下简称"《股东大会规则》"）、《西藏诺迪康药业股份有限公司章 程》（以下简称"《公司章程》"）及其他相关法律法规的规定,就 公司本次股东大会的召集、召开程序、召集人资格、出席会议人员的 资格、表决程序等有关事项出具本法律意见书。 本所律师出具法律意见,仅依据本法律意见书出具日以前发生或 者存在的事实,并基于本所律师对有关法律法规和规范性文件的理解 而形成。在法律意见书中,本所律师仅就公司本次股东大会的召集、 召开程序及召集人资格、出席会议人员的资格、议案的提出、股东大 会的表决程序等事项进行审查和见证后发表法律意见,不对本次 股东 大会所审议议案的内容以及在议案中所涉及的事实和数据的真实性 和准确性等问题发表意见。 一、本次股东大会的 ...

证券代码：600211 证券简称：西藏药业 公告编号：2023-041 西藏诺迪康药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 22 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 138,081,727 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 55.6920 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (一) 股东大会召开的时间：2023 年 09 月 11 日 (二) 股东大会召开的地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 1、公司在任董事 9 人，出席 9 人； 2、公司在任监事 3 人，出席 3 人； 3、董事会秘书出席本次会议；其他高管列席了本次 ...

西藏诺迪康药业股份有限公司 关于召开 2023 年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本公司于2023年8月23日召开第八届董事会第二次会议，审议通过了《董事会提议召 开2023年第一次临时股东大会的议案》，公司将于2023年9月11日召开2023年第一次临时 股东大会，并发布了关于召开2023年第一次临时股东大会的相关通知（详见公司于2023年 8月25日发布在《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 www.sse.com.cn的相关公告）。为确保公司股东充分了解本次股东大会的相关信息，现将 有关事项提示公告如下： 一、 召开会议的基本情况 证券代码：600211 证券简称：西藏药业 公告编号：2023-040 (一) 股东大会类型和届次 2023 年第一次临时股东大会 股东大会召开日期：2023年9月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用 ...

证券代码：600211 证券简称：西藏药业 公告编号：2023-039 西藏诺迪康药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 9 月 14 日 15:00-16:00 ●会议召开方式：本次业绩说明会将采用网络方式举行 ●投资者可于 2023 年 9 月 13 日（星期三）前将相关问题通过电子邮件的形式发送至邮 箱：chenxu@xzyy.cn，本公司将在 2023 年半年度业绩说明会上对投资者普遍关注的问题进行 回答。 本公司已于 2023 年 8 月 25 日在《中国证券报》《上海证券报》《证券时报》及上海证券 交易所网站（www.sse.com.cn）披露公司 2023 年半年度报告，为便于广大投资者更全面深入 了解公司 2023 年半年度的经营成果、财务状况，公司计划于 2023 年 9 月 14 日 15:00-16:00 召开 2023 年半年度业绩说明会，就投资者普遍关心的问题进行交流。 一、说明会类型 ...

西藏诺迪康药业股份有限公司 2023 年第一次临时股东大会文件 1 目 录 | 1、2023年半年度利润分配方案 . | | --- | 2 议案一： 2023 年半年度利润分配方案 各位股东： 公司2023年半年度实现的归属于母公司所有者的净利润为595,904,757.58元（未经审 计）；截止2023年6月30日，公司未分配利润为1,739,842,061.25元。 为了更好地回报投资者，公司结合目前的实际经营状况，拟在2023年半年度进行现金 分红，具体方案如下：以实施利润分配方案之股权登记日可参与分配的总股本为基数，向 全体股东按每10股派发现金12.02元(含税), 合计拟派发现金红利298,021,287.29元（含 税），本半年度公司现金分红比例为50.01%。 如在本方案披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/股 权激励授予股份回购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司 拟维持现金派发总额不变，相应调整每股分配比例。如后续总股本发生变化，将另行公告 具体调整情况。 上述议案已经公司第八届董事会第二次会议审议通过，并于2023年8月25日在《中国 ...

Financial Performance - The company's revenue increased by 35.52%, while the net profit attributable to shareholders grew by 127.23%[24] - The total profit for the period was 98.89 million RMB, with no adverse factors impacting this figure[24] - The company's revenue for the first half of 2023 reached ¥1,820,236,994.97, representing a 35.52% increase compared to ¥1,343,187,984.10 in the same period last year[46] - Net profit attributable to shareholders for the same period was ¥595,904,757.58, a significant increase of 127.23% from ¥262,250,027.50 year-on-year[46] - Basic earnings per share for the first half of 2023 were ¥2.40, a 126.42% increase from ¥1.06 in the same period last year[46] - The weighted average return on equity increased by 8.73 percentage points to 18.23% compared to 9.50% in the previous year[46] - The company's main business revenue for the first half of 2023 reached CNY 1,817.52 million, a year-on-year increase of 35.52%[51] - The net profit attributable to shareholders for the same period was CNY 595.90 million, reflecting a significant growth of 127.23% year-on-year[51] Production and Capacity - The company has modern production lines for various dosage forms, ensuring sufficient capacity for sales growth[30] - The company is expanding the production capacity of its main product, Xinhua Su, to reach an annual capacity of 15 million units, with construction and equipment debugging completed[76] - The production model is based on "sales-driven production," aligning production plans with annual sales forecasts from distributors[48] Research and Development - The main product, Xinhuisu, is a unique gene-engineered drug for treating acute heart failure, with increasing sales and a competitive advantage in the market[30] - The company has introduced new product forms, such as the granule version of Nuodikan, which offers better absorption and bioavailability[30] - The company is actively researching artificial cultivation techniques for endangered Tibetan medicinal materials, ensuring long-term resource availability[30] - The company has initiated research on the artificial cultivation of other Tibetan medicinal materials, such as Hongjing Tian[55] - The company is conducting research on artificial cultivation of Rhodiola and other Tibetan medicinal materials, with multiple suitable varieties identified for introduction[80] Marketing and Brand Development - The marketing system is well-established nationwide, providing effective support for market competitiveness[30] - The company is actively promoting brand awareness through sponsorship of national sports events, enhancing product visibility[57] - The company has been recognized as the first high-tech pharmaceutical listed company in Tibet and has built three GMP-compliant production bases[49] Financial Management - Financial expenses decreased by 20.77 million RMB year-on-year, primarily due to rising interest income from USD deposits[24] - The company's total assets increased by 18.30% to ¥4,849,558,902.31 compared to ¥4,099,412,305.94 at the end of the previous year[46] - The net cash flow from operating activities was ¥544,852,090.83, up 14.66% from ¥475,187,904.79 in the previous year[46] - The company's trading financial assets increased by 33.77% to ¥1,060,076,514.14 from ¥792,490,921.85 year-on-year[86] - The company’s investment activities generated a net cash outflow of ¥522,582,953.76, compared to a net outflow of ¥274,449,809.74 in the previous year[82] Environmental Management - The company reported a total wastewater discharge of 0.134 tons for chemical oxygen demand (COD) with a concentration of 17.39 mg/L in the first half of the year[98] - The company has a wastewater treatment capacity of 240 m³/d established in 2002, which is currently stable[99] - The company has implemented an emergency response plan for environmental incidents, which is filed with the environmental protection department[102] - The company has not faced any administrative penalties for environmental issues during the reporting period[102] Investments and Acquisitions - The company has invested a total of ¥746 million in the Sputnik-V vaccine project, with delays in technology transfer and increased uncertainty regarding export sales leading to a provision for impairment losses of ¥327.29 million[109] - The company has obtained sales rights for four in-development products from its investment in Amite, with two products already receiving medical device registration and production licenses, while the other two remain under development[109] Related Party Transactions - The total amount of related party transactions for the period was RMB 969,774,470.80, compared to RMB 698,966,972.75 in the previous period[132] Cash Flow and Assets - The company reported a cash balance of approximately ¥476.78 million, with ¥4 million restricted as a loan guarantee[65] - The company’s cash and cash equivalents stood at RMB 102,199,110.39 as of December 31, 2022[125] - The company’s cash and cash equivalents increased to RMB 2,473,965.67 from RMB 1,167,386.81 at the beginning of the period[168]

关于 2023 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●每股分配比例：A 股每 10 股派发现金红利 12.02 元(含税)。 ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在权益 分派实施公告中明确。 ●在实施权益分派的股权登记日前公司总股本发生变动的，拟维持现金派发总额不变， 相应调整每股派发金额，并将另行公告具体调整情况。 一、利润分配方案内容 公司 2023 年半年度实现的归属于母公司所有者的净利润为 595,904,757.58 元（未经 审计）；截止 2023 年 6 月 30 日，公司未分配利润为 1,739,842,061.25 元。 证券代码：600211 证券简称：西藏药业 公告编号：2023-035 西藏诺迪康药业股份有限公司 1 （一）公司第八届董事会第二次会议以 9 票同意，0 票反对，0 票弃权，审议通过了《2023 年半年度利润分配预案》，本方案符合《公司章程》规定的利润分配政策等相关规定。 （二）独立董事意见：公司为了更 ...

Financial Performance - Revenue for the first quarter reached ¥906,936,646.41, an increase of 38.22% compared to the same period last year[3] - Net profit attributable to shareholders was ¥303,199,537.33, reflecting a growth of 73.59% year-over-year[3] - Net profit after deducting non-recurring gains and losses was ¥292,663,191.66, up 60.31% from the previous year[3] - Basic and diluted earnings per share were both ¥1.22, marking a 74.70% increase compared to the same quarter last year[3] - The company's net profit for Q1 2023 reached CNY 305,515,106.51, a significant increase from CNY 176,249,968.12 in Q1 2022, representing a growth of approximately 73.2%[23] - Total operating revenue for Q1 2023 was CNY 336,808,266.54, compared to CNY 197,920,331.83 in Q1 2022, indicating a year-over-year increase of about 70.1%[23] - The total comprehensive income for Q1 2023 was RMB 334,185,286.51, compared to RMB 171,724,467.56 in Q1 2022, representing a year-over-year increase of approximately 94.5%[45] - Basic and diluted earnings per share for Q1 2023 were both RMB 1.22, up from RMB 0.70 in Q1 2022, indicating a growth of 74.3%[45] Cash Flow and Assets - Operating cash flow for the period was ¥383,734,010.64, representing a 58.30% increase year-over-year[3] - Cash flow from operating activities increased to CNY 974,382,793.17 in Q1 2023, up from CNY 727,580,990.05 in Q1 2022, marking a growth of around 33.9%[24] - The company reported a net cash increase of CNY 97,654,907.96 in cash and cash equivalents for Q1 2023, compared to a decrease of CNY 59,236,552.05 in Q1 2022[29] - The total cash outflow from investing activities was $735.46 million, compared to $400.81 million in the same period last year, resulting in a net cash flow from investing activities of $55.06 million, a significant improvement from a net outflow of $98.06 million in Q1 2022[53] - The cash and cash equivalents at the end of Q1 2023 amounted to $1.47 billion, a significant increase from $928.64 million at the end of Q1 2022[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,657,241,109.95, up 13.61% from the end of the previous year[4] - The company's total assets increased to approximately RMB 4.66 billion, up from RMB 4.10 billion in the previous period, representing a growth of about 13.5%[21] - Total current liabilities increased to RMB 1.25 billion, up from RMB 1.03 billion, reflecting a growth of approximately 21.8%[21] - The total liabilities increased to $570.81 million in Q1 2023, compared to $483.45 million in Q1 2022, reflecting a growth of 18.1%[55] - The total equity increased to $3.60 billion in Q1 2023, up from $3.40 billion in Q1 2022, representing a growth of 5.8%[55] Shareholder Information - Total number of common shareholders at the end of the reporting period was 41,195[16] - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 80,033,379 shares, accounting for 32.28% of total shares[16] Research and Development - Research and development expenses decreased compared to the previous year, contributing to the overall profit growth[14] - Research and development expenses decreased to CNY 4,473,040.54 in Q1 2023 from CNY 9,926,809.57 in Q1 2022, reflecting a reduction of approximately 55.1%[23] Strategic Initiatives - The company has identified potential market expansion opportunities and is focusing on new product development[22] - The company is exploring strategic mergers and acquisitions to enhance its market position[22] - The company has established a cash management strategy to optimize its financial resources[22] - The company plans to continue expanding its market presence and investing in new technologies and products, although specific details were not disclosed in the call[45] - The company is actively exploring new financial products and market expansion strategies, as indicated by its ongoing financial management plans[38]